Hasil Pencarian - Brian Elliott

  • Menampilkan 1 - 3 hasil dari 3
Perbaiki Hasil
  1. 1
    Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma

    Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma oleh Sally D Miller, Greta Lozano-Ortega, Alex Mutebi, Owanate Briggs, Kavita Sail, Brian Elliott, Anupama Kalsekar

    Diterbitkan 2022-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS

    P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS oleh Allison Rosenthal, Monika Jun, Javier Munoz, Tongsheng Wang, Alex Mutebi, Anthony Wang, Shibing Yang, Kojo Osei-Bonsu, Brian Elliott, Anupama Kalsekar, Fernando Rivas Navarro, Andrew Ip

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

    Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in... oleh Allison Rosenthal, Javier Munoz, Monika Jun, Tongsheng Wang, Alex Mutebi, Anthony Wang, Shibing Yang, Kojo Osei-Bonsu, Brian Elliott, Fernando Rivas Navarro, Junhua Yu, Samantha Brodkin, Mariana Sacchi, Andrew Ip

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: